Pushes Into Phase 3 With Strong Momentum Viking Therapeutics advanced its dual GLP-1/GIP agonist VK2735 into Phase 3 after achieving 14.7% weight loss without plateauing in Phase 2, positioning the program as a serious challenger in a rapidly expanding $150B obesity market
For pouchitis in adults and children, an eight-strain formulation, comprising L
It is essential to note that recovery times are influenced by the severity of the injury and the area being treated
P5 showed a greatly diminished efficacy and potency ( E max =29 and 32%
On December 20, 2024, Eli Lilly announced the FDA has approved Zepbound (tirzepatide) as the first and only prescription medication for adults with moderate-to-severe obstructive sleep apnea and obesity. AASM.org Among persons with moderate-to-severe obstructive sleep apnea and obesity, tirzepatide reduced the AHI, body weight, hypoxic burden, hsCRP concentration, and systolic blood pressure and improved sleep-related patient-reported outcomes. NIH study Can the makers of these new weight loss medications really claim to treat and cure Obstructive Sleep Apnea (OSA)
People are talking about a patch that claims to bump up your Basal Metabolic Rate (BMR), potentially torching an extra 500 calories every single day
